SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY ARTICLE M impact

Novo Nordisk shares fall nearly 2% after two trial cancellations

Novo Nordisk stock traded at $46.60 Monday, down nearly 2%, after Reuters reported it stopped two ziltivekimab heart-failure trials.

NOVOBNVO
SquawkNews Desk

Novo Nordisk NYSE:NVO traded at $46.60 on Monday, down nearly 2%, after Reuters reported the company stopped two ziltivekimab heart-failure trials, even as the stock’s investment case was viewed as being pulled in opposite directions.

Related stories

Asian session market picture: S&P 500 +0.56%, Nasdaq 100 +1.24%; USD/JPY +0.11%, WTI +0.66%, 9984 leads volume Asian session market picture. US index futures: S and P futures is up 0.56 percent, Nasdaq futures is up 1.24 percent, Dow futures is up 0.28 percent and Russell futures is up 0.35 M impact | EQUITY | Nov 11, 2026, 03:30 AM UTC Samsung Electronics shares rise 3% M impact | EQUITY | Nov 11, 2026, 03:20 AM UTC Mebuki Financial Raises Annual Dividend Forecast to ¥48 Per Share Mebuki Financial Raises Annual Dividend Forecast to ¥48 Per Share Mebuki Financial Group raised L impact | EQUITY | Nov 11, 2026, 03:09 AM UTC Mebuki Financial Group to Buy Back Up to 0.95% of Shares Mebuki Financial Group plans a share buyback worth up to 10 billion yen. L impact | EQUITY | Nov 11, 2026, 03:02 AM UTC Asian session market picture: S&P 500 +0.44%, Nasdaq 100 +0.96%; USD/JPY +0.06%, WTI +0.56%, 9984 leads volume Asian session market picture. US index futures: S and P futures is up 0.44 percent, Nasdaq futures is up 0.96 percent, Dow futures is up 0.19 percent and Russell futures is up 0.23 M impact | EQUITY | Nov 11, 2026, 03:00 AM UTC Japan’s Nikkei rises for a third day Japan’s Nikkei rose for a third day. The headline attributes the move to data and earnings fueling AI optimism. M impact | EQUITY | Nov 11, 2026, 02:51 AM UTC